Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age

Shunsuke Kiuchi*, Shinji Hisatake, Takayuki Kabuki, Takashi Oka, Shintaro Dobashi, Yoshiki Murakami, Takahide Sano and Takanori Ikeda

Abstract

Background: Elderly patients with heart failure (HF) have been observed to decrease activities of daily living (ADL) during hospitalization. Prevention of ADL decline from shortening of hospital stays is especially important in the elderly, because decreasing ADL is associated with poor prognosis. We investigated the relationship between the early initiation of tolvaptan (TLV) after hospitalization and the length of hospital stay in patients with HF aged younger than 80 years and aged 80 years and older.

Methods: We analyzed 146 patients younger than 80 years (< 80) and 101 patients aged 80 years and older (≥ 80) who were hospitalized with HF from February 2011 to June 2016 and had initiated TLV. The relationship between the time until commencement of TLV and the length of hospital stay was assessed. Additionally, a comparison made between the TLV early start group (within the median) and the delayed start group (over the median) for both groups. Multivariate analysis was also performed on factors that required hospital stays below the median.

Results: A significant correlation was observed between time to TLV initiation and the length of hospital stay (< 80: r = 0.382, P < 0.001; ≥ 80: r = 0.395, P < 0.001). The length of hospital stay in the early group was significantly longer than that in the delayed group for both groups (< 80: early 21.0 ± 13.0 days and 33.0 ± 22.7 days, respectively, P < 0.001; ≥ 80: early 21.3 ± 12.5 days and 32.9 ± 17.9 days, respectively, P < 0.001). Conversely, no statistically significant difference found in the length of hospital stay after initiation of TLV. Moreover, no increase in adverse events in the elderly observed. A multivariate analysis revealed that a predictive factor for short-term hospitalization was early administration of TLV regardless of age.

Conclusions: The early initiation of TLV after hospitalization was associated with a shorter length of hospital stay in patients with HF regardless of age.

Keywords: Tolvaptan, The Length of hospital stay, Heart failure, Elderly

Background

Tolvaptan (TLV), oral selective vasopressin type 2 receptor antagonists, approved in Japan in October 2010. In the United States and Europe, TLV used for hyponatremia and/or syndrome of inappropriate antidiuretic hormone. In Japan, TLV also became available for fluid retention due to heart failure (HF) [1]. Moreover, the V2 receptor antagonist effect of TLV has been suggested to have an effect on improving HF beyond its diuretic effect [2].

The prevalence of HF increases with aging. In Japan, which is facing an aging society, the number of patients with HF is expected to reach approximately 1.3 million in
HF was diagnosed according to the Framingham criteria, from February 2011 to June 2016 and started with TLV. Study participants consent. Of the ethics committee granted a waiver for informed present study, Toho University Omori Medical Center in the study (opt-out). Due to retrospective nature of the given the opportunity to decline to be further enrolled disclosed on the website of Toho University Omori Medical Center. Therefore, we have posted the details of the study in opt-out format (granted a waiver of informed consent study was a retrospective, observational study at a single accordance with the Declaration of Helsinki. The present material and methods

The ethics committee of Toho University Omori Medical Center approved the present study (approval number: M18271_17318). All experiments were performed in accordance with the Declaration of Helsinki. The present study was a retrospective, observational study at a single center. Therefore, we have posted the details of the study in opt-out format (granted a waiver of informed consent from study participants). Details about this study were disclosed on the website of Toho University Omori Medical Center and our department (Department of Cardiovascular Medicine) and the potential participants were given the opportunity to decline to be further enrolled in the study (opt-out). Due to retrospective nature of the present study, Toho University Omori Medical Center of the ethics committee granted a waiver for informed consent.

Study participants

We enrolled 369 patients who were hospitalized for HF from February 2011 to June 2016 and started with TLV. HF was diagnosed according to the Framingham criteria, the American Heart Association guidelines, or the European Society of Cardiology guidelines. The exclusion criteria were as follows: died in hospital, transferred to another hospital, and a clinical scenario classification (CS) of 4 or 5. Ultimately, 146 patients younger than 80 years (<80) and 101 patients 80 years of age and older (≥80) were investigated. The CS is a selection criterion to determine the treatment method in hospitalized patients with early-stage HF. It is typically decided by blood pressure (BP), except CS4 (acute coronary syndrome) and CS5 (isolated right HF) [9]. CS1-3 is decided as follows: CS1, elevated SBP (≥140 mm Hg); CS2, normal SBP (100 and ≤140 mm Hg); CS3, low SBP (<100 mm Hg).

Study outcomes

The main outcomes in both groups were the relationship between the time from hospitalization to commencement of TLV, and the length of hospital stay. We also investigated the time until commencement of TLV from hospitalization. These times were compared between the early use group (within the median day of TLV initiation) and the delayed use group (more than the median day of TLV initiation), in both the ≥80 group and the <80 group. The findings in the ≥80 group were compared with those in the <80 group.

Moreover, the patient characteristics between early and delayed commencement of TLV in both the ≥80 group and the <80 group were compared. Multivariate analysis was also performed on factors that required hospital stays below the median.

We also investigated the safety of TLV (its adverse effects and whether or not it can be continued). For safety, hypernatremia, the incidence of serious liver and/or renal dysfunction, and adverse events (AEs) were investigated. Hypernatremia was defined as a serum sodium concentration below 150 mEq/L at baseline and above 150 mEq/L after treatment [10]. An AE was defined as any medical occurrence that was life threatening or that required inpatient hospitalization.

Clinical profiles

We investigated levels of HF (New York Heart Association [NYHA] classification), the CS, medical history, and underlying heart disease. Hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, and prior HF hospitalization were assessed for the medical history. Underlying heart disease was classified into ischemic cardiomyopathy (ICM), hypertensive heart disease (HHD), valvular heart disease (VHD), tachycardia-induced cardiomyopathy (TIC), dilated cardiomyopathy (DCM), and others.

Additionally, we investigated age, gender, height, weight, and body mass index (weight [kg]/height² [m²]).
Concomitant medications
Concomitant medications were also investigated. We recorded the TLV administration rate and the dosage at discharge, as well as the presence or absence of combined RAS inhibitors at the start of TLV. For diuretics, we investigated the administration rates and the dosage of loop diuretics. The dose of loop diuretic was calculated in terms of furosemide (furosemide 20 mg is equivalent to azosemide 30 mg). Patients receiving loop diuretics had been receiving furosemide or azosemide. As for cardio protective medications, the administration rates of RAS inhibitors and BBs at discharge were recorded. An RAS inhibitor was defined as angiotensin converting enzyme inhibitor (in the present study, patients had been receiving imidapril, perindopril, or enalapril) or angiotensin II type1a receptor blocker (in the present study, patients had been receiving candesartan, valsartan, irbesartan, azilsartan, losartan, olmesartan, or telmisartan).

Physiological function examinations
We measured systolic BP and diastolic BP (dBP) using an aneroid sphygmomanometer on admission and at discharge. The heart rate (HR) was measured in the supine position by standard 12-lead electrocardiography on admission.

Transthoracic echocardiography was investigated by 2 blinded physicians. We assessed left ventricular systolic function (EF), which was calculated using the Teichholz method using the parasternal long-axis view, or modified Simpson’s method by an apical 2- or 4-chamber view [11]. Patients were classified into HFrEF and HfPEF as per the Japan Circulation Society [5], and HfPEF was defined as EF > 50% [12]. The proportions of HFrEF and HfPEF were also evaluated.

Laboratory data and chest X-ray
We measured C-reactive protein, electrolytes (sodium and potassium), liver function, renal function, hemoglobin, and brain natriuretic peptide (BNP). For liver function, aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase were measured. Similarly, to determine renal function, we investigated blood urea nitrogen, creatinine, and the estimated glomerular filtration rate (eGFR). The eGFR was calculated according to the Japanese Society of Nephrology criteria: eGFR = 194 × Cr – 1.094 × age – 0.287 for men and 194 × Cr – 1.094 × age – 0.287 × 0.739 for women [13].

Physicians calculated the cardiothoracic ratio from chest X-ray film utilizing the maximal cardiac diameter and the intrathoracic diameter in a blinded manner.

Statistical analysis
The continuous variables were expressed as mean ± standard deviation. We compared the groups employing an unpaired Student’s t-test. A probability (p) value of less than 0.05 was considered to indicate statistical significance. A Windows computer (Excel, Microsoft XP) and EZR (Saitama Medical Center, Jichi Medical University) were used, which is a graphical user interface for R version 2.13.0 (The R Foundation for Statistical Computing, Vienna, Austria) [14].

Results
Comparison of characteristics between patients 80 years and older and patients younger than 80
The clinical profiles of the ≥ 80 patients were compared with those patients < 80 (Table 1). In the elderly, there were many women with a physique. No statistically significant differences in medical history were observed between the 2 groups. NYHA and CS classifications were similar in the 2 groups.

Underlying heart diseases in the elderly were ICM (40 patients, 27.4%), HHD (25 patients, 17.1%), VHD (27 patients, 18.5%), TIC (23 patients, 15.8%), DCM (20 patients, 13.7%), and others (11 patients, 15.8%). Similarly, ICM (39 patients, 38.6%), HHD (6 patients, 5.9%), VHD (36 patients, 35.6%), TIC (12 patients, 11.9%), DCM (1 patient, 0.9%), and others (7 patients, 6.9%) were found in the < 80 group. No significant differences were observed between the 2 groups.

In a laboratory analysis, no significant difference was found in the BNP (Table 2). Conversely, significant differences were identified in hemoglobin (Hb) and folic acid (Table 2). The proportions of HFrEF and HfPEF were also evaluated.

Table 1 Patients’ clinical profiles
|                      | <80 years old | ≥80 years old | P value |
|----------------------|--------------|--------------|---------|
| Age (years)          | 67.5 ± 10.0  | 85.1 ± 3.7   | <0.001  |
| Male (n, %)          | 94, 64.4     | 48, 47.5     | <0.001  |
| Height (cm)          | 160.5 ± 9.0  | 154.9 ± 8.6  | <0.001  |
| Weight (kg)          | 56.5 ± 13.5  | 46.9 ± 9.5   | <0.001  |
| Body mass index (kg/m²) | 21.8 ± 4.1  | 19.5 ± 3.4   | <0.001  |
| NYHA class (II/III/IV) | 1/122/23    | 1/88/12      | 0.376   |
| CS class (I/II/III)  | 48/83/15     | 25/66/10     | 0.270   |
| Hypertension (n, %)  | 112, 76.7    | 82, 81.2     | 0.402   |
| Diabetes mellitus (n, %) | 37, 25.3    | 23, 22.8     | 0.645   |
| Dyslipidemia (n, %)  | 29, 19.9     | 26, 25.7     | 0.277   |
| Chronic kidney disease (n, %) | 18, 12.3   | 20, 19.8     | 0.110   |
| Prior HF hospitalization (n, %) | 54, 37.0    | 45, 44.6     | 0.234   |

NYHA: New York Heart Association, CS: clinical scenario, HF: heart failure. Continuous data are expressed as the mean ± standard deviation or error. P-values were determined using the unpaired t-test.
differences were found in dBP on admission and at discharge, HR, hemoglobin, and EF between the 2 groups, and the older elderly population accounted for more patients with HFpEF than the younger elderly population.

Baseline characteristics between the early and delayed commencement of TLV in both the ≥ 80 group and the < 80 group are shown in Tables 3 and 4. In the group older than 80 years, there were significantly differences in CS, BP and BNP. However, there were no statistically differences in the group younger than 80 years.

**Tolvaptan and heart failure in the study participants**
The association between the length of hospital stay and the time until commencement of TLV from hospitalization is illustrated in Fig. 1 (for ≥ 80) and Fig. 2 (for < 80). Both indicated a significant positive correlation.

The median of the time until initiation of TLV from hospitalization in the ≥ 80 and < 80 groups were 5 and 4 days, respectively. In the ≥ 80 group, the length of hospital stay and time until commencement of TLV from hospitalization in the early use group were significantly shorter than those of the delayed use group (the length of hospital stay: 21.3±12.5 and 32.9±17.9, respectively, P<0.001; time until commencement of TLV from hospitalization: 3.0±1.3 and 13.6±11.6, respectively, P<0.001) (Table 3). These results were similar in the < 80 group (the length of hospital stay: 21.0±13.0 and 33.0±22.7, respectively, P<0.001; time until commencement of TLV from hospitalization: 2.5±1.0 and 12.7±13.3, respectively, P<0.001) (Table 4). On the other hand, there were no significant differences in the length of hospital stay after initiation of TLV in either group (≥ 80 group: 18.3±12.4 and 19.3±12.7, P=0.699; < 80 group: 18.6±13.1 and 20.3±16.9, P=0.479) (Tables 3 and 4).

In addition, a multivariate analysis revealed that a predictive factor for short-term hospitalization in the ≥ 80 group was early administration of TLV (Table 5). These results were similar in the < 80 group (Table 6).

Comparing the 2 groups, no significant differences were observed in the administration rate or the dosage of TLV at discharge in the ≥ 80 group compared with the < 80 group: the administration rate of TLV was 47 (46.5%) patients vs 73 (50%) patients, respectively, P=0.594; the dosage of TLV was 7.33±3.92 mg/day vs 8.30±4.70 mg/day, respectively, P=0.092, respectively) (Table 7).

**Concomitant medications between each group**
In a comparison between the ≥ 80 and < 80 groups, there were no significant differences in TLV-related findings (Table 7). Similarly, loop diuretic-related findings showed
no significant differences; however, the dosage of diuretics (TLV and loop diuretics) was lower in the ≥ 80 than the <80 group. No statistical difference was observed in cardio protective medications between the groups.

**Safety of tolvaptan**
Of 247 patients, hypernatremia incidence was observed in 4 (1.62%) patients. Two (2.0%) patients were included in the ≥80 group. Another 2 (1.4%) patients were included in the <80 group, and there were no statistical

### Table 3  Patient characteristics in the group older than 80 years

|                                | Early use of TLV (n = 40) | Delayed use of TLV (n = 61) | P value |
|--------------------------------|---------------------------|----------------------------|--------|
| Body mass index (kg/m²)        | 19.4 ± 2.9                | 19.7 ± 4.2                 | 0.603  |
| NYHA class (II/III/IV)         | 0/55/6                    | 1/33/6                     | 0.705  |
| CS class (I/II/III)            | 19/38/4                   | 6/28/6                     | 0.026  |
| Systolic BP (mm Hg) on admission | 130.8 ± 22.7              | 121.5 ± 19.9               | 0.037  |
| Diastolic BP (mm Hg) on admission | 70.3 ± 13.8               | 64.1 ± 11.5                | 0.020  |
| Heart rate (bpm)               | 82.5 ± 20.5               | 85.5 ± 23.7                | 0.506  |
| AST (IU/L)                     | 34.0 ± 22.8               | 40.9 ± 47.0                | 0.329  |
| ALT (IU/L)                     | 24.1 ± 18.2               | 31.5 ± 53.4                | 0.323  |
| eGFR (ml/min/1.73 m²)          | 43.8 ± 19.4               | 40.5 ± 22.8                | 0.431  |
| Hemoglobin (g/dL)              | 11.4 ± 1.9                | 11.0 ± 2.1                 | 0.326  |
| Brain natriuretic peptide (pg/mL) | 1502.2 ± 211.9           | 850.2 ± 96.8              | 0.019  |
| Ejection fraction (%)          | 51.0 ± 18.1               | 55.1 ± 18.5                | 0.268  |
| HFpEF (n, %)                   | 30, 49.2                  | 23, 57.5                   | 0.418  |
| Length of hospital stay        | 21.3 ± 12.5               | 32.9 ± 17.9                | <0.001 |
| Time until commencement of TLV from hospitalization | 3.0 ± 0.3  | 13.6 ± 1.16                | <0.001 |
| Length of hospital stay after initiation of TLV | 18.3 ± 12.4 | 19.3 ± 12.7               | 0.699  |

**Table 4  Patient characteristics in the group younger than 80 years**

|                                | Early use of TLV (n = 79) | Delayed use of TLV (n = 67) | P value |
|--------------------------------|---------------------------|----------------------------|--------|
| Body mass index (kg/m²)        | 21.7 ± 3.9                | 21.9 ± 4.2                 | 0.778  |
| NYHA class (II/III/IV)         | 1/68/10                   | 0/54/13                    | 0.203  |
| CS class (I/II/III)            | 26/46/7                   | 23/36/8                    | 0.760  |
| Systolic BP (mm Hg) on admission | 131.7 ± 28.0              | 128.6 ± 31.7               | 0.533  |
| Diastolic BP (mm Hg) on admission | 69.7 ± 22.2               | 75.7 ± 17.9                | 0.073  |
| Heart rate (bpm)               | 89.0 ± 23.5               | 94.7 ± 28.8                | 0.195  |
| AST (IU/L)                     | 62.4 ± 24.5               | 73.6 ± 24.9                | 0.750  |
| ALT (IU/L)                     | 51.6 ± 21.8               | 62.0 ± 25.2                | 0.754  |
| eGFR (ml/min/1.73 m²)          | 49.0 ± 26.5               | 43.3 ± 21.5                | 0.156  |
| Hemoglobin (g/dL)              | 12.6 ± 2.2                | 12.0 ± 3.2                 | 0.229  |
| Brain natriuretic peptide (pg/mL) | 1153.2 ± 1180           | 1529.3 ± 284.8             | 0.199  |
| Ejection fraction (%)          | 45.3 ± 17.6               | 43.2 ± 19.5                | 0.509  |
| HFpEF (n, %)                   | 31, 39.2                  | 25, 37.3                   | 0.813  |
| Length of hospital stay        | 21.0 ± 13.0               | 33.0 ± 22.7                | <0.001 |
| Time until commencement of TLV from hospitalization | 2.5 ± 1.0  | 12.7 ± 13.3                | <0.001 |
| Length of hospital stay after initiation of TLV | 18.6 ± 13.1 | 20.3 ± 16.9               | 0.479  |

NYHA: New York Heart Association, CS: clinical scenario, BP: blood pressure, AST: aspartate aminotransferase, ALT: alanine aminotransferase, eGFR: estimated glomerular filtration rate, HFpEF: heart failure preserved ejection fraction, TLV: tolvaptan. Continuous data are expressed as the mean ± standard deviation or error. P-values were determined using the unpaired t-test.
differences between the groups. No case of serious hypernatremia or central pontine myelinolysis was observed. Moreover, no case of serious liver or renal dysfunction was reported. Serious AEs were not detected.

**Discussion**

**Comparison of baseline characteristics in heart failure**

The EF in the ≥ 80 group was statistically higher than that in the < 80 group, and the proportion of HFrEF in the ≥ 80 group was significantly higher than that in the < 80 group. These results were consistent with the characteristics of HF among the elderly in Japan. A previous study had reported that patients with HFrEF included more elderly and women, and they had anemia. Conversely, patients with HFrEF had high heart rates [15]. The participants in the present study included patients with backgrounds that matched several of these characteristics. In addition, the length of hospital stay for HF in Japan is reported to be approximately 20 days [16]. Therefore, the present study reflected the real world experience of HF, although only those who received TLV were included.

**The length of hospital stays in elderly patients with heart failure**

Bed rest and oxygen administration are necessary for the treatment of HF; however, these often cause a decrease in the ADL of elderly patients hospitalized with HF. Long-term bed rest has been associated with increased in-hospital death from HF [17], and the prognosis of HF worsens when physical activity decreases during hospitalization [18]. Particularly, muscle weakness in elderly patients during hospitalization is a factor of poor prognosis comparable to HF; therefore, shortened bed rest and early discharge are important [19]. The early initiation of TLV has been reported to shorten bed rest in elderly patients with HF [20]. In the present study, the early initiation of TLV shortened the length of hospital stay even among patients 80 years and older, and a significant positive correlation found between time until initiation of TLV from hospitalization and the length of hospital stay. Additionally, only early administration of TLV was predicted to shorten hospitalization in both the over and < 80 groups.
Relationship between diuretics and the prognosis of elderly patients with heart failure

No significant difference found in the administration rate of TLV at discharge regardless of age, and approximately 50% of the patients continued TLV. Early initiation of TLV reported to be associated with the prognosis after discharge in patients requiring continued TLV [21]. Moreover, the administration of a higher dosage of loop diuretics could exacerbate HF [22]. These results are the same in elderly patients, and diuretics usage has been reported to be a prognostic factor in patients with HF 80 years and older. [23] In the present study, the dosage of diuretics (TLV and loop diuretics) was lower in the ≥80 than the <80 group, although there was no significant difference.
Safety of tolvaptan in heart failure patients older than 80 years

Tolvaptan (TLV) can easily maintain renal hemodynamics and renal function, because TLV mainly removes water from the third space [24]. However, high TLV dosage has been reported to worsen renal function [25]. In the present study, the early initiation of TLV did not increase the dosage significantly. Moreover, TLV post-marketing surveillance has reported some physician-reported adverse drug reactions [26]. No AEs were observed in either group in the present study. TLV has also been reported to be used without increased AEs, even in patients older than 85 years [27]. Therefore, TLV can be used relatively safely even in older patients with HF with careful follow-up.

Study limitations

The present study was a single-center, retrospective, observational study. The attending physicians determined the use of TLV, because the study was designed from the retrospective, not interventional, perspective. The choice of medications could have been influenced by the patients' baseline characteristics. Additionally, the manner in which TLV is used changes from year to year. Tolvaptan's prescription rate has increased, and the time until commencement of TLV from hospitalization has shortened year by year [28]. The continuation of TLV at discharge has also been reported to contribute to the improvement in prognoses [29], and the continuation after discharge is increasing annually. These potential biases could have affected the results. Therefore, further large, prospective, clinical studies are required to confirm these results. In addition, ADL was not evaluated, and the relationship between ADL and length of hospital stay was unclear, because the present study was a retrospective study. ADL before administration of TLV was also unclear.

Conclusion

The early initiation of Tolvaptan was associated with a shorter length of hospital stay in patients with HF, both in those aged younger than 80 years and in those aged 80 years and older.

Abbreviations

TLV: Tolvaptan; HF: Heart failure; HFrEF: Heart failure reduced ejection fraction; HFpEF: Heart failure preserved ejection fraction; BB: β-Blocker; RAS:

| Table 6 | Multivariate analysis for prediction of short-term hospitalization in the group younger than 80 years |
|---------|---------------------------------------------------------------------------------------------------|
|         | HR       | p value | HR       | p value | HR       | p value |
| Early administration of TLV | 1.210    | < 0.001 | 1.200    | < 0.001 | 1.190    | < 0.001 |
| Age (years) | 0.998    | 0.904   | 0.925    | 0.104   | 0.960    | 0.918   |
| BMI (kg/m²) | 1.130    | 0.595   | 1.000    | 0.919   | 2.040    | 0.159   |
| Sex (men) | 0.960    | 0.918   | 0.900    | 0.957   | 0.105    | 0.588   |
| Clinical scenario 1 | 0.940    | 0.379   | 0.960    | 0.558   | 0.920    | 0.205   |
| Systolic BP (mm Hg) | 1.000    | 0.919   | 0.998    | 0.904   | 0.990    | 0.904   |
| NYHA | 0.950    | 0.589   | 1.000    | 0.878   | 0.950    | 0.589   |
| BNP (pg/dl) | 0.950    | 0.589   | 0.990    | 0.092   | 0.950    | 0.589   |
| Hemoglobin (g/dl) | 0.917    | 0.205   | 0.950    | 0.589   | 0.917    | 0.205   |

TLV: tolvaptan, BMI: body mass index, BP: blood pressure, NYHA: New York Heart Association Classification, BNP: brain natriuretic peptide. The multivariate analysis was performed applying Cox proportional hazards models.

| Table 7 | Patients’ concomitant medications |
|---------|----------------------------------|
|         | < 80 years old (n = 146) | ≥ 80 years old (n = 101) | P value |
| Administration rate of TLV at discharge (n, %) | 83, 50.0 | 47, 46.5 | 0.594 |
| Dosage of TLV at discharge (mg/day) | 8.30 ± 4.70 | 7.33 ± 3.92 | 0.092 |
| Presence rate of RAS-I combined use at the start of TLV (n, %) | 107, 73.3 | 83, 82.2 | 0.104 |
| Administration rate of loop diuretics at discharge (n, %) | 111, 76.0 | 82, 81.2 | 0.337 |
| Dosage of loop diuretics at discharge (mg/day) | 29.1 ± 23.3 | 24.5 ± 14.0 | 0.115 |
| Administration rate of beta-blockers at discharge (n, %) | 122, 83.6 | 80, 79.2 | 0.386 |
| Administration rate of ACE-Is/ARBs at discharge (n, %) | 90, 61.6 | 57, 56.4 | 0.414 |

TLV: Tolvaptan, ACE-I: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor blocker. Continuous data are expressed as the mean ± standard deviation. P-values were determined using the unpaired t-test.
Renin–angiotensin–aldosterone system, ADL. Activities of daily living, AE. Adverse event; NHYA: New York Heart Association classification; CS: Clinical scenario classification; ICM: Ischemic cardiomyopathy; HHF: Hypertensive heart disease; VAL: Valvular heart disease; TIC: Tachycardia-induced cardio- myopathy; DCM: Dilated cardiomyopathy; BMI: Body mass index; sBP: Systolic blood pressure; dBP: Diastolic blood pressure; HR: Heart rate; TEE: Transtho- racic echocardiography; EF: Ejection fraction; Hb: Hemoglobin; BNP: Brain natriuretic peptide; BUN: Blood urea nitrogen; Cre: Creatinine; eGFR: Estimated glomerular filtration rate.

Acknowledgements
The authors thank all participants who contribute to the present study.

Author contributions
SK conceived the article. And, all authors contributed to data collection and analysis. All authors have read and approved the final version.

Funding
This manuscript was supported in part by Grants-in-Aid (19K08408 to S.K.) for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Availability of data and materials
The datasets generated and/or analysed during the current study are not pub- licly available due additional analysis is currently underway but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The present study is approved by the ethics committee of Toho University Omon Medical Center (approval number: M18271_17318). All experiments were performed in accordance with the Declaration of Helsinki. Comprehensive agreement was obtained from all patients from the opt-out method on the web-site of Toho University Omon Medical Center and our department (Department of Cardiovascular Medicine), Due to retrospective nature of the present study, Toho University Omon Medical Center of the ethics committee granted a waiver for informed consent.

Consent for publication
Not applicable.

Competing interests
T.I. has received Honoraria (e.g. lecture fees) from Bayer Healthcare, Ono Pharmaceuticaal Co., Ltd. And, T.I. has received Subsidies or Donations from Daiichi Sankyo. The remaining authors declare that they have no competing interests.

Received: 29 June 2021 Accepted: 19 April 2022 Published online: 29 April 2022

References
1. Matsuzaki M, Hori M, Izumi T, Fukunami M. Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25(Suppl 1):S33–45.
2. Imamura T, Kinugawa K, Hatano M, et al. Low cardiac output stimulated vasopressin release in patients with stage d heart failure. Circ J. 2014;78:2259–67.
3. Okura Y, Ramadan MM, Sato N, et al. Characteristics and outcomes of super-elderly patients (aged ≥ 90 years) hospitalized for heart failure-analysis of a nationwide inpatient database. Circ Rep. 2020;2:393–9.
4. Kuchí S, Hisatake S, Kabuki T, et al. The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients. Heart Vessels. 2018;33:367–73.
5. Mebazaa A, Gheorghiade M, Piña IL, et al. Practical recommendations for prehospital and early in-hospital management of patients present- ing with acute heart failure syndromes. Crit Care Med. 2008;36(Suppl 1):S129–139.
6. Akitá K, Kohsaka S, et al. West Tokyo Heart Failure Registry Investigators. Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival. Int J Cardiol. 2017;235:162–8.
7. Kaneko H, Itoh H, Yotsumoto H, et al. Characteristics and outcomes of super-elderly patients (aged ≥ 90 years) hospitalized for heart failure-analysis of a nationwide inpatient database. Circ Rep. 2020;2:393–9.
8. Kuchí S, Hisatake S, Kabuki T, et al. The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients. Heart Vessels. 2018;33:367–73.
9. Mebazaa A, Gheorghiade M, Piña IL, et al. Practical recommendations for prehospital and early in-hospital management of patients present- ing with acute heart failure syndromes. Crit Care Med. 2008;36(Suppl 1):S129–139.
10. Kinugawa K, Sato N, Inomata Y, Yasuda M, Shibasaki Y, Shimakawa T. Novel risk score efficiently prevents tolvaptan-induced hypernatremic events in patients with heart failure. Circ J. 2018;82:1344–50.
11. Schiller NB, Shah PN, Crawford M, et al. Recommendations for quantita- tion of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358–67.
12. Kuchí S, Hisatake S, Kabuki T, et al. Effect of switching from Cilnidipine to Azelnidipine on cardiac sympathetic nerve function in patients with heart failure preserved ejection fraction. Int Heart J. 2018;59:120–5.
13. Matsuio S, Ima E, Hono M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
14. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.
15. Tsucahishi-Makaya M, Hamaguchi S, Kinugawa S, et al. J-CARE-CARD Investigators: Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (J-CARE-CARD). Circ J. 2009;73:1893–900.
16. Mitani H, Funakubo M, Sato N, et al. In-hospital resource utilization, wors- ening heart failure, and factors associated with length of hospital stay in patients with hospitalized heart failure: a Japanese database cohort study. J Cardiol. 2020;76:342–9.
17. Biagi P, Gussoni G, Ioni L, et al. CONFINE Study Group. Clinical profile and predictors of in-hospital outcome in patients with heart failure: the FADOI “CONFINE” study. Int J Cardiol. 2011;152:88–94.
18. Uemura Y, Shibata R, Takemoto K, et al. Prognostic impact of the preserva- tion of activities of daily living on post-discharge outcomes in patients with acute heart failure. Circ J. 2018;82:2793–9.
19. Gallego González E, Ortiz Alonso FJ, Vidán Astiz MT, et al. Development and validation of a prognostic index for 6- and 12-month mortality in hospitalized older adults. Arch Gerontol Geriatr. 2017;73:269–78.
20. MatsuKawa R, Kubota T, Okabe M, Yamamoto Y, Meno H. Efficacy and safety of the early use of tolvaptan in elderly patients with decompenated heart failure. Heart Vessels. 2018;33:145–54.
21. Matsumura K, Morishita S, Taniguchi N, et al. Prognostic factors for long- term outcomes in acute decompensated heart failure patients under tolvaptan treatment. Heart Vessels. 2019;34:607–15.
22. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:1064–9.
23. Hamaguchi S, Kinugawa S, Goto D, et al. J-CARE-CARD Investigators. Pre- dictors of long-term adverse outcomes in elderly patients over 80 years hospitalized with heart failure. A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (J-CARE-CARD). Circ J. 2011;75:2403–10.
24. Kuchí S, Ikeda T. Hemodynamic and hormonal effects of tolvaptan for heart failure. Intern Med. 2019;58:471–5.
25. Kinugawa K, Sato N, Inomata Y, Yasuda M, Shimakawa T, Fukuta Y. Real- world effectiveness and tolerability of tolvaptan in patients with heart failure-final results of the Samsca post-marketing surveillance in heart failure (SAHLE) study. Circ J. 2019;83:1520–7.
26. Nikura H, Iijima R, Anzai H, et al. Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure. Anatol J Cardio. 2017;18:206–12.
28. Kuragaichi T, Sato Y. Temporal trends of a vasopressin V2 receptor antagonist in heart failure using a nationwide database in Japan. ESC Heart Fail. 2020;8:527–38.
29. Imamura T, Kinugawa S, Muramatsu T, et al. Long-term tolvaptan treatment in refractory heart failure. Circ Rep. 2019;1:431–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.